Abstract 157P
Background
The Lung Cancer Policy Network, a global multi-stakeholder initiative of experts in lung cancer, has developed a global interactive map of low-dose CT (LDCT) lung cancer screening implementation research. The map aims to visualise the evidence on how LDCT screening is being implemented around the world, including all relevant ongoing and recently completed implementation studies, national/regional organised programmes, and clinical trials.
Methods
A structured search of peer-reviewed and grey literature identified a preliminary list of ongoing LDCT screening programmes and studies completed since 2015. Findings were used to develop a comprehensive research methodology to guide the development of a framework for data extraction of over 70 variables (e.g. inclusion criteria, integration with smoking cessation programmes, quality control protocols). Members of the Network provided ongoing guidance of the development of the map, and a draft of each entry is sent to the lead of each study/programme for validation. The data set will be updated on a biannual basis.
Results
To date, 133 entries have been included. The first edition of the data set was made publicly available online in November 2022. Ongoing research for the second edition will expand the dataset to include organised programmes in the US and studies that ended since 2010. When complete, contents will be visualised as data dashboards with filters to enable analysis of how implementation has been achieved. Interrogation of the map will provide evidence from real-world implementation on how to: model lung cancer risk; embed smoking cessation interventions into the screening pathway; mitigate barriers to participation; or optimise quality assurance. Outcome data (e.g. proportion of participants diagnosed with stage I/II lung cancer) are also collected and can be assessed for how they concord with clinical trial evidence.
Conclusions
This is, to our knowledge, the first global database of LDCT screening implementation. Findings may provide a valuable resource to those implementing LDCT screening programmes, and offer insights to policymakers on how to ensure the feasibility, cost-effectiveness, equity, and quality of screening within their populations.
Legal entity responsible for the study
The Health Policy Partnership.
Funding
The Lung Cancer Policy Network is a global multi-stakeholder initiative set up by the Lung Ambition Alliance. The Network is funded by AstraZeneca, Guardant Health, Johnson & Johnson, Medtronic and MSD. Secretariat is provided by The Health Policy Partnership, an independent health research and policy consultancy. All Network outputs are non-promotional, evidence based and shaped by the members, who provide their time for free.
Disclosure
E. Wheeler: Financial Interests, Personal, Writing Engagements, The Health Policy Partnership (the organization where Eleanor Wheeler is employed) provides Secretariat duties for the Lung Cancer Policy Network, which received funding from AstraZeneca, Guardant, Medtronic, Johnson & Johnson and Merck, Sharpe & Dohme (MSD) for the research that and development of the interactive map which is described in this abstract. Eleanor Wheeler has not received any direct consultancy fees for any of this work: The Health Policy Partnership; Financial Interests, Institutional, Full or part-time Employment, The Health Policy Partnership has been commissioned over the past 36 months to conduct non-promotional, non-product related policy projects for: Alexion, All.Can International, Amazon Web Services, Amgen, AstraZeneca, Advanced Accelerator Applications, Batten Disease Family Association (BDFA), Bristol Myers Squibb (BMS), Boehringer Ingelheim, European Federation of Pharmaceutical Industries and Associations (EFPIA), Elekta, European Multiple Sclerosis Platform (EMSP), European Society of Anaesthesiology and Intensive Care (ESAIC), Fragility Fractures Network (FFN), Global Heart Hub (GHH), Guardant Health, Heart Valve Voice Canada, Indivior, Initiative Herzklappe e.V, Janssen Pharmaceutica NV, Johnson & Johnson, Medicines for Europe, Medtronic, Merck Sharpe & Dohme (MSD), Neuroendocrine Cancer UK, National Institute for Prevention and Cardiovascular Health (NIPC), Novartis, Novo Nordisk, Philips, Roche Diagnostics, Sanofi, Vifor Pharma, and UCB. Eleanor Wheeler has not received any direct consultancy fees for any of this work: The Health Policy Partnership; Non-Financial Interests, Personal, Member, Current member since October 2021: The European Society of Medical Oncology; Non-Financial Interests, Personal, Member: The International Association for the Study of Lung Cancer (IASLC). D. Bancroft: Financial Interests, Personal, Full or part-time Employment, The Health Policy Partnership (the organization where Dani Bancroft is employed) HPP provides Secretariat duties for the Lung Cancer Policy Network, which received funding from AstraZeneca, Guardant, Medtronic, Johnson & Johnson and Merck, Sharpe & Dohme (MSD) for the research that and development of the interactive map which is described in this abstract. Dani Bancroft has not received any direct consultancy fees for any of this work: The Health Policy Partnership; Financial Interests, Institutional, Funding, The Health Policy Partnership has been commissioned over the past 36 months to conduct non-promotional, non-product related policy projects for: Alexion, All. Can International, Amazon Web Services, Amgen, AstraZeneca, Advanced Accelerator Applications, Batten Disease Family Association (BDFA), Bristol Myers Squibb (BMS), Boehringer Ingelheim, European Federation of Pharmaceutical Industries and Associations (EFPIA), Elekta, European Multiple Sclerosis Platform (EMSP), European Society of Anaesthesiology and Intensive Care (ESAIC), Fragility Fractures Network (FFN), Global Heart Hub (GHH), Guardant Health, Heart Valve Voice Canada, Indivior, Initiative Herzklappe e.V, Janssen Pharmaceutica NV, Johnson & Johnson, Medicines for Europe, Medtronic, Merck Sharpe & Dohme (MSD), Neuroendocrine Cancer UK, National Institute for Prevention and Cardiovascular Health (NIPC), Novartis, Novo Nordisk, Philips, Roche Diagnostics, Sanofi, Vifor Pharma, and UCB. Dani Bancroft has not received any direct consultancy fees for any of this work: The Health Policy Partnership; Non-Financial Interests, Personal, Member, Member from October 2021 - October 2022: The European Society of Medical Oncology. S. Wait: Financial Interests, Personal, Invited Speaker, The Health Policy Partnership has been commissioned over the past 36 months to conduct non-promotional, non-product related policy projects for: Alexion, All. Can International, Amazon Web Services, Amgen, AstraZeneca, Advanced Accelerator Applications, Batten Disease Family Association (BDFA), Bristol Myers Squibb (BMS), Boehringer Ingelheim, European Federation of Pharmaceutical Industries and Associations (EFPIA), Elekta, European Multiple Sclerosis Platform (EMSP), European Society of Anaesthesiology and Intensive Care (ESAIC), Fragility Fractures Network (FFN), Global Heart Hub (GHH), Guardant Health, Heart Valve Voice Canada, Indivior, Initiative Herzklappe e.V, Janssen Pharmaceutica NV, Johnson & Johnson, Medicines for Europe, Medtronic, Merck Sharpe & Dohme (MSD), Neuroendocrine Cancer UK, National Institute for Prevention and Cardiovascular Health (NIPC), Novartis, Novo Nordisk, Philips, Roche Diagnostics, Sanofi, Vifor Pharma, and UCB. Suzanne Wait has not received any direct consultancy fees for any of this work: The Health Policy Partnership; Financial Interests, Personal, Writing Engagements, The Health Policy Partnership (the organization where Suzanne Wait is employed) provides Secretariat duties for the Lung Cancer Policy Network, which received funding from AstraZeneca, Guardant, Medtronic, Johnson & Johnson and Merck, Sharpe & Dohme (MSD) for the research that and development of the interactive map which is described in this abstract. Suzanne Wait has not received any direct consultancy fees for any of this work: The Health Policy Partnership; Financial Interests, Institutional, Full or part-time Employment, The Health Policy Partnership has been commissioned over the past 36 months to conduct non-promotional, non-product related policy projects for: Alexion, All.Can International, Amazon Web Services, Amgen, AstraZeneca, Advanced Accelerator Applications, Batten Disease Family Association (BDFA), Bristol Myers Squibb (BMS), Boehringer Ingelheim, European Federation of Pharmaceutical Industries and Associations (EFPIA), Elekta, European Multiple Sclerosis Platform (EMSP), European Society of Anaesthesiology and Intensive Care (ESAIC), Fragility Fractures Network (FFN), Global Heart Hub (GHH), Guardant Health, Heart Valve Voice Canada, Indivior, Initiative Herzklappe e.V, Janssen Pharmaceutica NV, Johnson & Johnson, Medicines for Europe, Medtronic, Merck Sharpe & Dohme (MSD), Neuroendocrine Cancer UK, National Institute for Prevention and Cardiovascular Health (NIPC), Novartis, Novo Nordisk, Philips, Roche Diagnostics, Sanofi, Vifor Pharma, and UCB. Suzanne Wait has not received any direct consultancy fees for any of this work: The Health Policy Partnership; Financial Interests, Personal, Ownership Interest, Suzanne Wait is a shareholder of The Health Policy Partnership and serves as Managing Director: The Health Policy Partnership; Non-Financial Interests, Personal, Member, Active member July 2016 - Present: The European Society of Medical Oncology.